Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients
A Randomized, Double Blind Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of Single and Multiple Ascending Doses of QBW251 in Healthy Subjects and Multiple Doses in Cystic Fibrosis Patients
Sponsor: Novartis Pharmaceuticals
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Novartis Pharmaceuticals
Other Cystic Fibrosis trials with similar outcome
A PHASE1/PHASE2 clinical study on Cystic Fibrosis, this trial is terminated or withdrawn. The trial is conducted by Novartis Pharmaceuticals and has accumulated 9 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
May 2019 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — May 2019 [monthly]
Terminated PHASE1_PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
Phase: PHASE2 → PHASE1_PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .